The article reviews the role of the NOD-like receptor 3 (NLRP3) inflammasome in the pathogenesis of lifestyle-related disorders, including obesity, hyperlipidemia, diabetes, chronic respiratory diseases, oral diseases, and cardiovascular diseases. NLRP3 is a key component of the innate immune system, activated by various stimuli such as mitochondrial oxidation, reactive oxygen species (ROS), and receptor expression. Its activation leads to the release of proinflammatory cytokines and apoptosis, contributing to the development of these diseases. The review highlights the molecular mechanisms underlying NLRP3 activation and its downstream effects, emphasizing its role in regulating cell death and proliferation. It also discusses the therapeutic potential of targeting NLRP3 for the management and prevention of lifestyle-related disorders. Several clinical trials and drug candidates, such as dapansutril, senoflax, emlenoflax, NTO796, VTX2735, VTX3232, ZYL1, MCC950, BMS-986299, and IFM-2427, are mentioned as potential treatments for NLRP3-related conditions. The findings suggest that understanding and manipulating NLRP3 activation could lead to innovative therapeutic strategies for addressing lifestyle-related diseases.The article reviews the role of the NOD-like receptor 3 (NLRP3) inflammasome in the pathogenesis of lifestyle-related disorders, including obesity, hyperlipidemia, diabetes, chronic respiratory diseases, oral diseases, and cardiovascular diseases. NLRP3 is a key component of the innate immune system, activated by various stimuli such as mitochondrial oxidation, reactive oxygen species (ROS), and receptor expression. Its activation leads to the release of proinflammatory cytokines and apoptosis, contributing to the development of these diseases. The review highlights the molecular mechanisms underlying NLRP3 activation and its downstream effects, emphasizing its role in regulating cell death and proliferation. It also discusses the therapeutic potential of targeting NLRP3 for the management and prevention of lifestyle-related disorders. Several clinical trials and drug candidates, such as dapansutril, senoflax, emlenoflax, NTO796, VTX2735, VTX3232, ZYL1, MCC950, BMS-986299, and IFM-2427, are mentioned as potential treatments for NLRP3-related conditions. The findings suggest that understanding and manipulating NLRP3 activation could lead to innovative therapeutic strategies for addressing lifestyle-related diseases.